Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

Abstract Background Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes. Methods Initial stu...

Full description

Bibliographic Details
Main Authors: Jonathan F. Lovell, Yeong Ok Baik, Seuk Keun Choi, Chankyu Lee, Jeong-Yoon Lee, Kazutoyo Miura, Wei-Chiao Huang, Young-Shin Park, Sun-Je Woo, Sang Hwan Seo, Jae-Ouk Kim, Manki Song, Chung-Jong Kim, Jae-Ki Choi, Jieun Kim, Eun Ju Choo, Jung-Hyun Choi
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Medicine
Subjects:
COVID-19
SARS-CoV-2
RBD
Vaccine
Liposome
Adjuvant
Online Access:https://doi.org/10.1186/s12916-022-02661-1

Internet

https://doi.org/10.1186/s12916-022-02661-1

Similar Items